![Paolo Michieli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Paolo Michieli
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.
10
| Holding Company | Miscellaneous Commercial Services | 10 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Paolo Michieli via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Metabomed Ltd.
![]() Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer | |
University of Arizona | College/University | Undergraduate Degree | |
IGM BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
SHATTUCK LABS, INC. | Biotechnology | Director/Board Member | |
Welch Capital Partners LLC
![]() Welch Capital Partners LLC Investment ManagersFinance Welch Capital Partners LLC (WCP) is an independent registered investment advisor and hedge fund manager headquartered in Brooklyn, New York. The firm was founded by Leighton Welch in 1996. WCP provides investment advisory services to separately managed accounts as well as a long-short private limited partnership. | Investment Managers | Analyst-Equity | |
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Private Equity Analyst | |
Pontifax Management Co. Ltd.
![]() Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Investment Managers | Private Equity Analyst | |
TargEDys SA
![]() TargEDys SA BiotechnologyHealth Technology TargEDys SA develops microbiome-based solutions for appetite regulation. It provides humanity with easy means of regulating their eating behaviors for the third millennium. The company was founded by Pierre Dechelotte and Gregory Lambert 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
KEROS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Tel-Aviv University
![]() Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Graduate Degree | |
Gilda's Club New York City, Inc.
![]() Gilda's Club New York City, Inc. Miscellaneous Commercial ServicesCommercial Services Gilda's Club New York City, Inc. provides support services to cancer patients. Its programs include cancer support for all, offsite program, and programs for children and teens with cancer. The company was founded by Gene Wilder, Joanna Bull, Mandy Patinkin, and Joel Siegel in 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
Precirix NV
![]() Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Emergence Therapeutics AG
![]() Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Pharmaceuticals: Major | Director/Board Member | |
HepaRegeniX GmbH
![]() HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
![]() Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
University of Hohenheim | College/University | Undergraduate Degree | |
DiogenX SAS
![]() DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Biotechnology | Director/Board Member | |
FATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Redmile Group LLC
![]() Redmile Group LLC Investment ManagersFinance Redmile Group LLC (Redmile) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Jeremy Green and Michael Lee in 2007. Redmile provides investment management and advisory services to private investment funds and separately managed accounts. | Investment Managers | Founder | |
Maastricht University | College/University | Doctorate Degree | |
University of Aarhus | College/University | Doctorate Degree | |
ARGENX SE | Pharmaceuticals: Other | Founder | |
University of Utrecht | College/University | Corporate Officer/Principal | |
Université de Franche-Comté | College/University | Corporate Officer/Principal | |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder | |
University of Oxford | College/University | Doctorate Degree | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer | |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer | |
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Director/Board Member | |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
F-star Biotechnology Ltd.
![]() F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
SYNACT PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Synklino ApS
![]() Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | Medical/Nursing Services | Chairman | |
Danish Cancer Society
![]() Danish Cancer Society Miscellaneous Commercial ServicesCommercial Services The Danish Cancer Society provides support and resources for those affected by cancer, including patients and their families. The non-profit company is based in Copenhagen, Denmark and has subsidiaries in Denmark. The Danish company offers the latest information on patient involvement in cancer treatment and tools for utilizing patient-reported information. The organization also promotes cancer prevention through screening and works towards reducing the number of cancer cases and improving the quality of life for those who have survived cancer. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman | |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Chairman | |
Centauri Therapeutics Ltd.
![]() Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 11 |
Verenigd Koninkrijk | 8 |
Nederland | 6 |
Denemarken | 6 |
Frankrijk | 5 |
Sectoraal
Health Technology | 25 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 6 |
Distribution Services | 2 |
Operationeel
Director/Board Member | 27 |
Founder | 8 |
Chief Tech/Sci/R&D Officer | 5 |
Independent Dir/Board Member | 5 |
Corporate Officer/Principal | 4 |
Sterkste connecties
- Beurs
- Insiders
- Paolo Michieli
- Bedrijfsconnecties